Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

3.690 +0.330 (+9.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 3 4 Next >
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
3 Undervalued Biotech Stocks With Breakout Potential
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024
ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Where Zura Bio Stands With Analysts
 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
From Zura Bio Limited
Via Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation in June Investor Conferences
From Zura Bio Limited
Via Business Wire
3 Penny Stocks to Buy Now: May 2024
Penny stocks to buy carry a considerable amount of risk and extra sue dilligence is required before buying shares. 
Via InvestorPlace
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
From Zura Bio
Via Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Zura Bio Announces Participation at March Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation at February Investor Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
From Zura Bio Limited
Via Business Wire
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
From Zura Bio Limited
Via Business Wire
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
 
Via Benzinga
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
From Zura Bio Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2023
 
Via Benzinga
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.